Download
s00259-020-04744-8.pdf 130,46KB
WeightNameValue
1000 Titel
  • Brief progress report from the intersocietal working group on differentiated thyroid cancer
1000 Autor/in
  1. Verburg, Frederik A. |
  2. Ahuja, Sukhjeet |
  3. Avram, Anca M. |
  4. Bardiès, Manuel |
  5. Bernet, Victor |
  6. Bourguet, Patrick |
  7. Führer-Sakel, Dagmar |
  8. Draganescu, Ciprian |
  9. Daniels, Gilbert H. |
  10. Greenspan, Bennett |
  11. Gulec, Seza |
  12. Hegedüs, Laszlo |
  13. Jonklaas, Jacqueline |
  14. Luster, Markus |
  15. Oyen, Wim |
  16. Smit, Johannes |
  17. Tuttle, R. Michael |
  18. Zerdoud, Slimane |
  19. Van Nostrand, Douglas |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-12
1000 Erschienen in
1000 Quellenangabe
  • 47(6):1345-1347
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-020-04744-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188695/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated.!##!Methods!#!Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures.!##!Results!#!In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97-19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs.!##!Conclusions!#!This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml).
1000 Sacherschließung
lokal Thyroid Neoplasms/diagnostic imaging [MeSH]
lokal Adenocarcinoma [MeSH]
lokal Nuclear Medicine
lokal Research Report [MeSH]
lokal Humans [MeSH]
lokal Cardiology
lokal Imaging / Radiology
lokal Oncology
lokal Endocrinology
lokal Iodine Radioisotopes [MeSH]
lokal Editorial
lokal Orthopedics
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VmVyYnVyZywgRnJlZGVyaWsgQS4=|https://frl.publisso.de/adhoc/uri/QWh1amEsIFN1a2hqZWV0|https://frl.publisso.de/adhoc/uri/QXZyYW0sIEFuY2EgTS4=|https://frl.publisso.de/adhoc/uri/QmFyZGnDqHMsIE1hbnVlbA==|https://frl.publisso.de/adhoc/uri/QmVybmV0LCBWaWN0b3I=|https://frl.publisso.de/adhoc/uri/Qm91cmd1ZXQsIFBhdHJpY2s=|https://frl.publisso.de/adhoc/uri/RsO8aHJlci1TYWtlbCwgRGFnbWFy|https://frl.publisso.de/adhoc/uri/RHJhZ2FuZXNjdSwgQ2lwcmlhbg==|https://frl.publisso.de/adhoc/uri/RGFuaWVscywgR2lsYmVydCBILg==|https://frl.publisso.de/adhoc/uri/R3JlZW5zcGFuLCBCZW5uZXR0|https://frl.publisso.de/adhoc/uri/R3VsZWMsIFNlemE=|https://frl.publisso.de/adhoc/uri/SGVnZWTDvHMsIExhc3psbw==|https://frl.publisso.de/adhoc/uri/Sm9ua2xhYXMsIEphY3F1ZWxpbmU=|https://frl.publisso.de/adhoc/uri/THVzdGVyLCBNYXJrdXM=|https://frl.publisso.de/adhoc/uri/T3llbiwgV2lt|https://frl.publisso.de/adhoc/uri/U21pdCwgSm9oYW5uZXM=|https://frl.publisso.de/adhoc/uri/VHV0dGxlLCBSLiBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/WmVyZG91ZCwgU2xpbWFuZQ==|https://frl.publisso.de/adhoc/uri/VmFuIE5vc3RyYW5kLCBEb3VnbGFz
1000 Hinweis
  • DeepGreen-ID: a6b4f9f170f746d2ab7c527de16c7504 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6470188.rdf
1000 Erstellt am 2023-11-18T04:30:10.514+0100
1000 Erstellt von 322
1000 beschreibt frl:6470188
1000 Zuletzt bearbeitet 2023-12-01T11:18:32.258+0100
1000 Objekt bearb. Fri Dec 01 11:18:32 CET 2023
1000 Vgl. frl:6470188
1000 Oai Id
  1. oai:frl.publisso.de:frl:6470188 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source